Effects of Natural Products on Mcl-1 Expression and Function

被引：14

作者：

Muller, Florian ^{[1
]}

Cerella, Claudia ^{[1
]}

Radogna, Flavia ^{[1
]}

Dicato, Mario ^{[1
]}

Diederich, Marc ^{[2
]}

机构：

[1] Hop Kirchberg, Lab Biol Mol & Cellulaire Canc, L-2540 Luxembourg, Luxembourg

[2] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea

来源：

CURRENT MEDICINAL CHEMISTRY | 2015年 / 22卷 / 30期

基金：

新加坡国家研究基金会;

关键词：

apoptosis; cancer; Mcl-1; natural compounds; TRAIL-INDUCED APOPTOSIS; HUMAN MULTIPLE-MYELOMA; DOWN-REGULATES MCL-1; BCL-2 PROTEIN FAMILY; CELL-DEATH; SIGNAL TRANSDUCER; TARGETING MCL-1; PROSTATE-CANCER; INHIBITION; ACTIVATOR;

D O I：

10.2174/0929867322666150716115435

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Cancer development is mostly due to a deregulation of cell death as cancer cells become resistant to apoptosis by increasing expression of anti-apoptotic proteins belonging to the Bcl-2 family. Mcl-1 is one anti-apoptotic protein, which is mainly responsible for cancer cell resistance as it is overexpressed by most cancer cell types. Many research projects aim to restore cancer cell death by using natural pharmacological scaffolds targeting anti-apoptotic proteins to inhibit their effect in cancer development. This review introduces natural compound inhibitors of the Bcl-2 protein family with a focus on Mcl-1.

引用

页码：3447 / 3461

页数：15

共 50 条

[41] The role of glucocorticoid receptor phosphorylation in Mcl-1 and NOXA gene expression
Lynch, James T.
Rajendran, Ramkumar
Xenaki, Georgia
Berrou, Ilhem
Demonacos, Constantinos
Krstic-Demonacos, Marija
MOLECULAR CANCER, 2010, 9
[42] mir-29 regulates Mcl-1 protein expression and apoptosis
J L Mott
S Kobayashi
S F Bronk
G J Gores
Oncogene, 2007, 26 : 6133 - 6140
[43] The expression of Mcl-1 in human cervical cancer and its clinical significance
Zhang, Ting
Zhao, Chun
Luo, Liang
Zhao, Hua
Cheng, Jing
Xu, Fei
MEDICAL ONCOLOGY, 2012, 29 (03) : 1985 - 1991
[44] Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse
Kaufmann, SH
Karp, JE
Svingen, PA
Krajewski, S
Burke, PJ
Gore, SD
Reed, JC
BLOOD, 1998, 91 (03) : 991 - 1000
[45] Expression of Mcl-1 and Ki-67 in Papillary Thyroid Carcinomas
Maia, F. F. R.
Vassallo, J.
Pinto, G. A.
Pavin, E. J.
Matos, P. S.
Zantut-Wittmann, D. E.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2016, 124 (04) : 209 - 214
[46] The expression of Mcl-1 in human cervical cancer and its clinical significance
Ting Zhang
Chun Zhao
Liang Luo
Hua Zhao
Jing Cheng
Fei Xu
Medical Oncology, 2012, 29 : 1985 - 1991
[47] Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
Tantawy, Shady I.
Sarkar, Aloke
Hubner, Stefan
Tan, Zhi
Wierda, William G.
Eldeib, Abdelraouf
Zhang, Shuxing
Kornblau, Steven
Gandhi, Varsha
CLINICAL CANCER RESEARCH, 2023, 29 (02) : 446 - 457
[48] BRAF/MEK inhibitors selectively prime melanoma for Mcl-1 dependence and sensitize to Mcl-1 inhibition
Kump, Karson J.
Miao, Lei
Ansari, Nurul
Lombard, David B.
Nikolovska-Coleska, Zaneta
CANCER RESEARCH, 2019, 79 (13)
[49] Targeting Mcl-1 for the therapy of cancer
Quinn, Bridget A.
Dash, Rupesh
Azab, Belal
Sarkar, Siddik
Das, Swadesh K.
Kumar, Sachin
Oyesanya, Regina A.
Dasgupta, Santanu
Dent, Paul
Grant, Steven
Rahmani, Mohamed
Curiel, David T.
Dmitriev, Igor
Hedvat, Michael
Wei, Jun
Wu, Bainan
Stebbins, John L.
Reed, John C.
Pellecchia, Maurizio
Sarkar, Devanand
Fisher, Paul B.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (10) : 1397 - 1411
[50] Mcl-1 inhibitors: a patent review
Chen, Lijia
Fletcher, Steven
EXPERT OPINION ON THERAPEUTIC PATENTS, 2017, 27 (02) : 163 - 178

← 1 2 3 4 5 →